SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Salles Gilles)) mspu:(article)
 

Search: (WFRF:(Salles Gilles)) mspu:(article) > Real-world experien...

  • Hess, Georg (author)

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2022-10-18
  • Wiley,2023

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:b0e44972-9f0e-46af-838b-9e62451ebd08
  • https://lup.lub.lu.se/record/b0e44972-9f0e-46af-838b-9e62451ebd08URI
  • https://doi.org/10.1111/bjh.18519DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6–20.0) in the overall cohort, 5.5 months (95% CI 3.9–8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9–30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3–12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Dreyling, Martin (author)
  • Oberic, Lucie (author)
  • Gine, EvaHospital Clínic of Barcelona (author)
  • Zinzani, Pier Luigi (author)
  • Linton, Kim (author)
  • Vilmar, AdamOdense University Hospital (author)
  • Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund,Skåne University Hospital(Swepub:lu)onk-mje (author)
  • Chen, Jenny M.H. (author)
  • Ohler, Anke (author)
  • Stilgenbauer, StephanUniversity of Ulm (author)
  • Thieblemont, CatherineUniversité Paris Cité (author)
  • Lambert, JonathanUniversity College London Hospital (author)
  • Zilioli, Vittorio RuggeroNiguarda Hospital (author)
  • Sancho, Juan ManuelHospital Universitari Germans Trias i Pujol (author)
  • Ubieto, Ana Jimenez12 de Octubre University Hospital (author)
  • Fischer, Luca (author)
  • Eyre, Toby A.Oxford University Hospitals NHS Foundation Trust (author)
  • Keeping, Sam (author)
  • Park, Julie E. (author)
  • Wu, James J. (author)
  • Siddiqi, Rubina (author)
  • Reitan, John (author)
  • Wade, Sally (author)
  • Salles, GillesMemorial Sloan-Kettering Cancer Center (author)
  • Hospital Clínic of BarcelonaOdense University Hospital (creator_code:org_t)

Related titles

  • In:British Journal of Haematology: Wiley202:4, s. 749-7590007-10481365-2141

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view